Uterine Inflammatory Myofibroblastic Tumors: Proposed Risk Stratification Model Using Integrated Clinicopathologic and Molecular Analysis.
The American journal of surgical pathology
oregon; portland; chiles; Female; Humans; Middle Aged; Anaplastic Lymphoma Kinase; Receptor Protein-Tyrosine Kinases; Neoplasms, Connective and Soft Tissue; Granuloma, Plasma Cell; Uterus; Risk Assessment
Inflammatory myofibroblastic tumor (IMT) of the uterus is a rare mesenchymal tumor with largely benign behavior; however, a small subset demonstrate aggressive behavior. While clinicopathologic features have been previously associated with aggressive behavior, these reports are based on small series, and these features are imperfect predictors of clinical behavior. IMTs are most commonly driven by ALK fusions, with additional pathogenic molecular alterations being reported only in rare examples of extrauterine IMTs. In this study, a series of 11 uterine IMTs, 5 of which demonstrated aggressive behavior, were evaluated for clinicopathologic variables and additionally subjected to capture-based next-generation sequencing with or without whole-transcriptome RNA sequencing. In the 6 IMTs without aggressive behavior, ALK fusions were the sole pathogenic alteration. In contrast, all 5 aggressive IMTs harbored pathogenic molecular alterations and numerous copy number changes in addition to ALK fusions, with the majority of the additional alterations present in the primary tumors. We combined our series with cases previously reported in the literature and performed statistical analyses to propose a novel clinicopathologic risk stratification score assigning 1 point each for: age above 45 years, size≥5 cm,≥4 mitotic figures per 10 high-power field, and infiltrative borders. No tumors with 0 points had an aggressive outcome, while 21% of tumors with 1 to 2 points and all tumors with ≥3 points had aggressive outcomes. We propose a 2-step classification model that first uses the clinicopathologic risk stratification score to identify low-risk and high-risk tumors, and recommend molecular testing to further classify intermediate-risk tumors.
Women & Children
Obstetrics & Gynecology
Pathology & Laboratory Medicine
Ladwig, Nicholas R; Bean, Gregory R; Pekmezci, Melike; Boscardin, John; Joseph, Nancy M; Therrien, Nicole; Sangoi, Ankur R; Piening, Brian D.; Rajamanickam, Venkatesh; Galvin, Matthew; Bernard, Brady; Zaloudek, Charles; Rabban, Joseph T; Garg, Karuna; and Umetsu, Sarah E, "Uterine Inflammatory Myofibroblastic Tumors: Proposed Risk Stratification Model Using Integrated Clinicopathologic and Molecular Analysis." (2023). Articles, Abstracts, and Reports. 6769.